Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort
Professor Jean-Yves Blay and Professor Florence Duffaud
Exploring TKIs in metastatic sarcomas: Results of REGOBONE osteosarcoma cohort ( Professor Jean-Yves Blay and Professor Florence Duffaud )
14 Nov 2019
REGOSARC – activity of regorafenib in advanced non-adipocytic STS
Professor Jean-Yves Blay and Professor Florence Duffaud
REGOSARC – activity of regorafenib in advanced non-adipocytic STS ( Professor Jean-Yves Blay and Professor Florence Duffaud )
14 Nov 2019
Treatment pathways for patients with triple-negative breast cancer
Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA
Treatment pathways for patients with triple-negative breast cancer ( Elahe Salehi - Dana-Farber Cancer Institute, Boston, USA )
23 Oct 2019
The treatment landscape of occular melanoma
Maitry Patel CCPA - Princess Margaret Cancer Centre, Toronto, Canada
The treatment landscape of occular melanoma ( Maitry Patel CCPA - Princess Margaret Cancer Centre, Toronto, Canada )
21 Oct 2019
Immunotherapy in gastric cancers
Dr. Manish A. Shah - Mayo Clinic, Rochester, USA
Immunotherapy in gastric cancers ( Dr. Manish A. Shah - Mayo Clinic, Rochester, USA )
21 Oct 2019
The challenge of detecting NTRK fusions across tumour types
Professor Dr Marc Peeters, Professor Caterina Marchio
The challenge of detecting NTRK fusions across tumour types ( Professor Dr Marc Peeters, Professor Caterina Marchio )
21 Oct 2019
APAO: Providing support and opportunities for PAs
Jeremy Heinerich PA-C, DFAAPA - APAO Past President
APAO: Providing support and opportunities for PAs ( Jeremy Heinerich PA-C, DFAAPA - APAO Past President )
17 Oct 2019
GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanc...
Prof Jean Bourhis - Lausanne University Hospital, Lausanne, Switzerland
GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanced head and neck squamous cell carcinoma ( Prof Jean Bourhis - Lausanne University Hospital, Lausanne, Switzerland )
14 Oct 2019
Realising the potential of biosimilars
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Realising the potential of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019
Comment: Supporting a sustainable biosimilar solution
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Comment: Supporting a sustainable biosimilar solution ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019
Comment: Use of biosimilar monoclonal antibodies in the clinic
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Comment: Use of biosimilar monoclonal antibodies in the clinic ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019
Comment: Critical quality attributes of biosimilars
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Comment: Critical quality attributes of biosimilars ( Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands )
8 Oct 2019